Update to Drug Therapy Guidelines for Stelara and Rituximab
To: All Providers
Updated drug therapy guidelines for Stelara and Rituximab will be posted by March 1, 2020 and effective on April 1, 2020.
Stelara has recently been approved by the U.S. Food and Drug Administration (FDA) for an additional indication, the treatment of adults with Ulcerative Colitis. The updated criteria will reflect the plan-preferred medications for the treatment of this condition.
The updated guideline for Rituximab will include new criteria. Rituxan biosimilar products (Ruxience and Truxima) will be plan-preferred medications for newly started therapy and for conditions for which the plan-preferred biosimilar medication has been FDA-approved, or is supported by NCCN Guidelines® or NCCN Compendium® with a certain category of recommendation.
Working with Us
We want to hear from you! Have a topic request for the next Blue Bulletin? Email us
Stay in Touch! Sign up to receive emails for provider news and information